On September 5, 2025, China’s National Medical Products Administration (NMPA) officially approved Lancet Robotics’ RobPath-Spine® Surgery Navigation & Positioning System and RobPath® Knee Replacement Navigation System for market entry.

This regulatory milestone comes just months after Lancet Robotics secured a multi-million-dollar A+ funding round earlier in 2025 to accelerate its global expansion, scale up cross-specialty manufacturing, and drive R&D of next-generation surgical robotics.

Back in August 2023, Lancet Robotics’ RobPath Hip Replacement Navigation & Positioning System obtained NMPA registration, representing an early step into the total hip arthroplasty (THA) space. Together, these approvals highlight the company’s expanding presence across high-value surgical specialties.

Founded in 2018, Lancet Robotics is a Zhejiang “specialized and innovative” enterprise focusing on high-growth surgical fields including spine/trauma, joint replacement, dental implantation, and vascular intervention. Its interdisciplinary R&D team and strong collaborations with institutions such as Nanjing Drum Tower Hospital and the Second Affiliated Hospital of Zhejiang University underpin the development of full-cycle solutions — from AI-assisted diagnosis and personalized surgical planning to navigation robotics and postoperative evaluation.

Sep 10, 2025, MedChina